<SEC-DOCUMENT>0001104659-21-077001.txt : 20210604
<SEC-HEADER>0001104659-21-077001.hdr.sgml : 20210604
<ACCEPTANCE-DATETIME>20210604160635
ACCESSION NUMBER:		0001104659-21-077001
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210604
DATE AS OF CHANGE:		20210604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		21996496

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2118805d2_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a)<BR>
of the Securities Exchange Act of 1934</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed by
the Registrant </FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed
by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary
Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
Proxy Statement</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive
Additional Materials</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
Material Pursuant to &sect; 240.14a-12</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELLAS LIFE SCIENCES GROUP, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement if
Other Than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fee required.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class of securities to which transaction applies:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate number of securities to which transaction applies:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed maximum aggregate value of transaction:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total fee paid:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee
paid previously with preliminary materials.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount Previously Paid:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form, Schedule or Registration Statement No.:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Party:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Filed:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">On June 4, 2021, SELLAS Life
Sciences Group, Inc. published the transcript of its June 3, 2021 shareholder update call. A copy of the transcript can be found below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2118805d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>C O R P O R A T E&nbsp;&nbsp;&nbsp;P A R T I
C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Allison Soss, </B><I>Investor Relations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou, </B><I>Founder, President
 &amp; Chief Executive Officer </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>C O N F E R E N C E&nbsp;&nbsp;&nbsp;C A L L&nbsp;&nbsp;&nbsp;P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jason McCarthy, </B><I>Maxim Group</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Malloy (phon), </B><I>Alliance Global
Partners </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>P R E S E N T A T I O N</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greetings and welcome to the SELLAS Life Sciences
Group Shareholder Update Call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a reminder, this conference is being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would now like to turn the conference over to
your host, Ms. Allison Soss, Investor Relations for SELLAS Life Sciences Group. Thank you. You may begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Allison Soss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Melissa. Good morning, everyone, and
welcome to the SELLAS' Shareholder Update call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin, I would like to remind you that
SELLAS will be making statements on today's call relating to the future expectations regarding the further development of and regulatory
plans for GPS, its plans for NPS, the Company's financials, its discussions with potential partners and its corporate strategy. These
statements constituent forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform
Act of 1995 and, by their nature, involve estimates, projections, goals, forecasts and assumptions and are subject to risks and uncertainties,
which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company's clinical
plans, risks and uncertainties associated with the immunotherapy product development and clinical success thereof, the uncertainties of
regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs that could cause actual results or
outcomes to differ materially from those expressed in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements speak only as
of the date of this conference call and should not be relied upon as predictions for future events. While SELLAS may elect to update these
forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if the Company's views change.
Additional information about the material factors and assumptions forming the basis of the forward-looking statements and risk factors
can be found under the caption, &quot;Risk Factors,&quot; and SELLAS' annual report on Form 10-K filed on March 23, 2021 and in its other
SEC filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I would like to turn the call over
to Angelos Stergiou, President and Chief Executive Officer of SELLAS. Angelos?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Allison, and thank you, everyone, for
joining us today on our shareholder update call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, I would like to thank each and every one
of you, our shareholders, for your support and trust bestowed upon our Management team and our Company. I'm particularly grateful and
pleased to report that despite COVID-19 we remain clear in our mission and vision to develop and deliver complex and innovative treatments
for patients battling cancer. We're a small team but an experienced team that is dedicated and committed to seeing our lead clinical candidate,
galinpepimut-S, or GPS, through development so that it may one day make a difference in patients' lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I will provide some background for today's call
and will mainly focus on updates as they relate to clinical development, business development, commercial strategy and our financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of interest, we triggered an additional $1 million
milestone payment from our 3D Medicines licensing agreement just last week, which we expect to receive this month. As we have previously
stated, we expect to provide further clinical data in two studies, specifically in GPS combination with checkpoint inhibitors in ovarian
cancer and mesothelioma this month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As you may be aware, in December 2018, we entered
into a clinical collaboration and supply agreement with Merck &amp; Co. As it relates to the ovarian cancer GPS, pembrolizumab study,
we'll provide a further clinical data update, as I just mentioned, this month on this study once we have reviewed and assessed data with
our partner, Merck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before diving into the update, I'd like to provide
a brief introduction to SELLAS. A meet-and-greet, if you will.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The name SELLAS is derived from an ancient Greek
word that means truth and wisdom. So clinical research and development, we believe we can gain the insight and wisdom necessary to successfully
navigate the drug approval process. Our core mission is to prolong patients' lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I've been working in the biotechnology sector
for two decades now and have personally been actively involved in the immunotherapy and cancer vaccine space for the past 15 years. Prior
to founding SELLAS Life Sciences about 10 years ago, I helped develop, among others, one of the first cancer vaccines for lymphoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS is comprised of a highly experienced Management
team with strong oncology backgrounds. We are also fortunate to have a Board of Directors comprised of highly seasoned pharma, biotech,
science and finance professionals who support and guide our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, our Scientific Advisory Board consists
of truly eminent pioneers in the fields of cancer immunotherapy, chaired by Dr. Jeffrey Weber, a renowned specialist in immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We licensed GPS in 2014 from one of the world's
most renowned oncology centers and world-class laboratories at Memorial Sloan Kettering Cancer Center, specifically David Scheinberg's
lab in New York. Dr. Scheinberg is one of our Board Members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GPS is a novel therapeutic cancer vaccine that
targets the Wilms tumor, or WT1 antigen, the number one ranked cancer antigen by the National Cancer Institute, which is present and overexpressed
in about 20 tumor types, including hematological malignancies and solid tumors. GPS is a mixture of engineered and artificially mutated
peptides, i.e., the heteroclitic technology concept, and addresses 25 WT1 optimally selected epitopes. GPS has been shown in clinical
trials to elicit CD4, CD8 immune responses across the majority of HLA types.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that GPS has the potential to target
and destroy recurring tumor and residual cancer cells and to provide treatment for multiple indications to help cancer patients stay in
remission and live longer, with tolerable side effects. It is our belief that when a patient is treated with GPS the immune system is
basically given a picture of what the WT1 expressing malignant cancer cells look like and when they reappear the cytotoxic CD8 and CD4
(inaudible) 650 memory cells can be activated to fight off the cancerous cells which translates to survival benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When we licensed in GPS and to prepare for commercialization,
we reformulated the drug product from a liquid solution into a lyophilized powder product, resulting in a more efficient manufacturing
process. A lyophilized product is also more desirable than a liquid from a supply chain perspective. We introduced technical nuances in
the formulation and manufacturing, the result of which allows doctors to mix the vial of the lyophilized GPS product with saline and introduce
it via subcutaneous injection for an easy and quick administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are encouraged by the data seen to date in
the studies for GPS and we're very excited about the prospects for the GPS programs, both as a monotherapy and in combination with PD-1
inhibitors. Our current development program is focused on our registrational Phase 3 REGAL study of GPS as monotherapy in acute myeloid
leukemia, or AML, patients in second complete remission, as well as two earlier stage studies of GPS in combination with PD-1 inhibitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As for AML, the annual incidence rate of AML,
a debilitating disease, is around 80,000 patients in the U.S., EU, Japan and China. We estimate that approximately 15% of all new patients
with an AML diagnosis eventually are eligible for study entry per annum, and this also represents a total addressable market in this AML
CR2 indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our previous Phase 2 study, in the same patient
population as our Phase 3 trial that is in patients who achieved second remission, where patients die on average within three to six months
following achieving second remission, we observed the clinically and statistically significant survival benefit in patients who received
GPS versus concomitantly treated best standard therapy patients, an almost 16 month differential survival benefit, 21 months versus 5.4
months, with a P-value of 0.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key with our GPS therapy and AML as a monotherapy
seems to be the fact that patients are in remission. Similar to what we saw in patients in the second remission, we also saw survival
benefit in our studies in patients treated with GPS after achieving their first remission, or CR1. In our Phase 1 and Phase 2 studies
in the CR1 setting, we saw a prolonged median overall survival of 67.6 months in patients across all ages. If we look at the patients
60 years and older, who comprise the majority of the AML patients, the median overall survival was 32.2 months in the Phase 1 trial and
35.3 months in the Phase 2 trial compared to best standard treatment for this patient population, which is typically around 10 to 16 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on this aggregate set of encouraging results
and following discussions with the FDA, we initiated our Phase 3 AML CR2 REGAL study in early 2020. The trial design for the REGAL study,
an open label, randomized, multi-center Phase 3 trial was thoroughly reviewed and endorsed by our Scientific Advisory Board comprised
of top immuno-oncology world experts, as well as several top AML KOLs, as well as our Steering Committee. Our study design, including
biostatistics, was also discussed with the FDA. We plan to accrue 116 patients in approximately one hundred centers globally. We are fortunate
to be working with one of the top global CROs, PPD, on the REGAL study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients will be randomized to GPS versus best
available therapy in a one-to-one randomization. Best available therapy will consist of clinicians' choice of four regimens: observation,
hypomethylating agents, and/or the nedakleks (phon), and/or low dose saterobim (phon) 1110. The duration of GPS therapy is up to one year,
which will include an initial immunization induction phase, six injections given once every two weeks, followed by less frequently administered
boosters, for a total of up to 15 injections for the first one year regimen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, most patients in CR2 status are
rarely candidates for allogeneic stem cell transplant, primarily due to their advanced age and low level of medical fitness, or for several
other reasons, lack of compatible donors being a major factor. Typically, less than 10% of patients above 65 years of age, and less than
30% of younger patients, are able to undergo an allo transplant in CR2, especially if they had already received an allo transplant when
they were in CR1, i.e., prior to their relapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary endpoint of the REGAL study is overall
survival, and the study's powered at 90%, with assumptions of a median overall survival of only 10 months in the GPS arm, versus 5.4 months
in the best available treatment arm. To declare statistical significance, i.e., a positive study for efficacy, one would need either a
hazard ratio of less than 0.6 at interim analysis, or a hazard ratio of less than 0.675 at final analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interim analysis will consist of one single readout
for efficacy by the independent data monitoring committee after the first 80 deaths. Both the independent data monitoring committee and
the study steering committee have been established and consist of internationally renowned leukemia and biostatistical experts, including
Dr. Tom Fleming, the global principle investigator; Dr. Hagop Kantarjian, Chief of the Leukemia Department at the MD Anderson Cancer Center,
and the world renowned clinical trialist in AML responsible for the successful delivery of several agents currently FDA approved for this
malignancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If GPS is approved in the AML CR2 setting, this
will allow for GPS to enter the AML market and we'll then consider potential label expansion for the CR1 setting. It is absolutely feasible
and strategically sensible to consider a GPS study in patients older than 60 years in the AML CR1 space. This could be not only as a monotherapy,
but possibly as combination therapy with selected approved maintenance agents that are currently standard of care in the setting, such
as the MEDICAL-X (phon) and hypomethylating agents, or poised to soon become standard therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, again, assuming success in the AML CR2
study, we believe that there's significant opportunity for GPS to be the key anti-leukemic vaccine immunotherapy in various other settings
in AML, such as maintenance after allogeneic stem cell transplant, whereby GPS could potentially sensitize the donor's successful grafted
T-cells to prevent post-transplant leukemic relapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Independent Data Monitoring Committee is responsible
for reviewing and evaluating patient safety and efficacy data for the REGAL study. It is the only group that analyzes data independently,
and thus assesses the benefit/risk profile of GPS, and also monitors the quality and overall conduct to ensure the validity, scientific
and clinical merits of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, and very importantly, the Independent
Data Monitoring Committee may also, at its sole discretion, directly and independently liaise with the FDA in order to discuss potential
early discontinuation of the study in case of reliable evidence of safety and clinically significant positive efficacy of GPS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Independent Data Monitoring Committee has
met once thus far, and did not suggest any modifications to the trial design, nor the statistical plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have approval, in addition to the
United States, to open the REGAL study for enrollment in Germany, France and Greece, with additional approvals by European countries expected
very soon. Our focus is on countries with high AML incidence rates. We plan to activate at least 15 clinical sites in Europe this month.
We may also consider activating sites in other regions beyond the U.S. and the EU, which will enhance our commercial strategy around GPS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, we expect the interim analysis to
occur in the first half of 2022, provided that the ongoing COVID-19 pandemic does not significantly adversely impact our projected timeline
for enrollment. Assuming we receive positive data of the interim analysis, we will then prepare the BLA regulatory submission and submit
it to the FDA on a rolling basis due to our Fast Track designation, with potential approval and commencement of commercialization in late
2023. If the study proceeds beyond the interim analysis, we expect final data by the end of 2022, and the BLA filing in BS around mid
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now let's review the other WT1 positive GPS indications
we're currently studying in combination with checkpoint blockade inhibitors where we recently announced our patent issuance allowance,
which is indeed great news as it expands our intellectual property estate for GPS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential clinical efficacy of GPS as a checkpoint
inhibitor, such as pembrolizumab or Keytruda, or nivolumab or Opdivo, is premised upon the immunobiologic and pharmacodynamic synergy
between the two agents, whereby the tumor micro environment is mitigated by a checkpoint inhibitor, and thus allowing the patient's own
immune cells specifically sensitized against WT1 by GPS to invade and destroy cancerous cells. Our studies of GPS in combination with
PD-1 inhibitors concentrate on patients and tumor types with high WT1 expression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GPS was studied in combination with a PD-1 inhibitor,
Opdivo, in an IST study at Memorial Sloan Kettering, which evaluated the safety and efficacy of the GPS/Opdivo combination in patients
with recurring ovarian cancer who are in second or greater clinical remission. With a median follow-up of 33 months, we showed 30% of
patients being progression-free at two years, which compares to historical control rates of only 3% to 10% with best available treatment.
Notably, this was achieved without booster administration of GPS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2018, as I mentioned earlier, we entered
into a clinical trial collaboration and supply agreement with Merck &amp; Co. pursuant to which we initiated a Phase 1/2 multi-arm, basket
type clinical study of GPS in combination with Merck's anti-PD-1 therapy, Keytruda. We're currently focusing on second or third line WT1
positive relapse or refractory metastatic ovarian cancer patients by combining GPS with Keytruda in a Phase 2 study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We announced in December 2020 some initial data
from the first set of 80 valuable patients in this study showing a disease control rate, the sum of overall response rate and rate of
stable disease of 87.5% at a median follow-up of 9.4 weeks. We will provide a further clinical data update this month on this study once
we have reviewed and assessed data with our partner, Merck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the GPS PD-1 inhibitor combination
study in ovarian cancer, a Phase 1 IST clinical study in mesothelioma combining GPS with Opdivo is ongoing at Memorial Sloan Kettering
Cancer Center. Any prolongation of overall survival and/or progression-free survival greater than a few weeks would be considered clinically
meaningful considering the current lack of effective therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, we reported that the first set
of three valuable patients had a median progression-free survival rate of 10 weeks since therapy initiation. We expect to announce further
data by the end of this month as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moving on to our commercial strategy for GPS.
We entered into a license agreement with 3D Medicines for the development and commercialization rights of GPS for Greater China in December
of last year. We received an upfront payment of $7.5 million and the agreement provides for potential clinical, regulatory and commercial
milestone payments totaling up to an additional $194.5 million, plus royalties on future sales of GPS in Greater China. We have already
received the $1 million milestone and we have recently triggered a further $1 million milestone payment to be received within this month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We're also reviewing our options for commercialization
of GPS, assuming positive data and regulatory approval in the United States, the EU and the rest of the world beyond those places other
than Greater China. As you know, there are various ways to handle this, such as, for example, license, co-promote or co-market arrangements,
and we're assessing the path that will provide greatest value to you, our shareholders, as well as to patients. We are continuing to explore
other cancers, whether it's high WT1 expression and may make sense to pursue further clinical development of GPS, both as a monotherapy
and a combination, and potentially with a different technology application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As you can appreciate, once we have meaningful
and final update on any of the above, we will share those with you in due course.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let's move on to our second asset, nelipepimut-S,
or NPS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NPS is a monovalent, anti-HER2 immunotherapy vaccine
consisting of a sequence of nine immuno acids located in the extracellular domain of the HER2 protein on the surface of cancer cells and
select malignancies, mainly breast cancer, gastric cancer, and prostate cancer. NPS was invented by a renowned cancer immunologist and
clinical scientist at MD Anderson Cancer Center. Among them was Dr. George Peoples, a preeminent breast surgical oncologist and immunologist
with experience in several clinical trials of anticancer vaccines and was responsible for the U.S. Army cancer vaccine program. NPS was
licensed by MD Anderson and the Henry Jackson Foundation to Galena, and SELLAS acquired the program through the reverse merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We've been engaged in an ongoing effort to find
a license partner for the further development and commercialization of NPS following the positive data in 2018 in a (inaudible) of patients
with triple negative breast cancer, or TNBC, from a recently completed and published randomized Phase 2b study of NPS in combination with
trastuzumab in HER2 low-expressing breast cancer patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this study, clinically meaningful and statistically
significant results were seen in favor of the NPS plus trastuzumab combination adjuvant therapy in the 97 patient TNBC cohort. Specifically,
disease-free survival at the 24 month landmark was 92.6% for the combination arm, versus 70.2% in the control arm. Seventy five point
two percent reduction in risk of recurrence or death was documented at 24 months in favor of the combination therapy with a statistically
significant P-value of 0.013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interestingly, although all the various patient
subgroups within the TNBC cohort of the study showed benefit with the NPS plus trastuzumab combination, the greatest degree of reduction
in risk of recurrence or death at 24 months was seen in HLA-A24 positive patients reaching 90.6% of risk reduction. The comparison was
statistically significant with a P-value of 0.003. Of note, this HLA type is highly prevalent in Asia-Pacific basin patient populations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In patients with HER2 IRC 1/2 plus expression,
the combination of NPS plus trastuzumab markedly increases the abundance of HER2 peptide fragments including NPS on breast cancer cells
presented to antigen presenting cells through MHC Class 1 activation. This leads to marked stimulation or formation of antigen-specific
HER2 targeting CD8 cytotoxic t-lymphocyte in the vaccinated patients, leading to more efficient immunologically mediated breast cancer
cell killing. It is the highly stimulated CD8 cells that underlie the marked clinical effects seen with the combination of NPS plus trastuzumab
in TNBC patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following feedback from a Type C review with the
FDA, we finalized the design and plan for a Phase 3 registration enabling study of NPS in combination with trastuzumab for the treatment
of patients with TNBC in the adjuvant setting after standard treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We've also shown positive data with up to six
months follow-up from an investigator sponsored Phase 2 randomized trial, the VADIS study of NPS in combination with (inaudible) macrophage
(inaudible) stimulating factor, or GM-CSF in women with ductal carcinoma in situ, the breast based on a six month follow-up, which demonstrate
that CD8 T-cell responses persist long term post NPS treatment with treated patients retaining and modestly enhancing their antigen specific
immune response. This was highly statistically significant in favor of the NPS plus GM-CSF group with a P-value of less than 0.0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, in January of this year, the Data Safety
Monitoring Board recommended, with respect to the ongoing investigator sponsored study of NPS plus trastuzumab, in higher risk HER2 3+
breast cancer patients that, given the small size of the study and in order to preserve the statistical power, that the primary analysis
of the study be done upon the completion of three years of follow-up on every patient or until more events are collected, which we expect
to occur by the end of this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In seeking potential outlicensing opportunities
to fund and conduct the future clinical development of NPS, it is very important to us and for our shareholders, as well as all the other
stakeholders involved, the licensors of NPS, MD Anderson Cancer Center and the Henry Jackson Foundation, TNBC patients, the treating physicians,
that we find the right partner so we can maximize value for our shareholders, as well as for the licensors of NPS, as importantly, to
provide for the opportunity for NPS to go to market and to get to market and provide another option for TNBC patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have made it a priority to find the company
that we believe has both the financial resources as well as the capabilities and the true desire from a clinical development, regulatory
and commercial perspective to execute on a Phase 3 program for NPS and successfully bring this product candidate to TNBC patients, who
do not have many treatment choices, as well as provide value to our shareholders through market terms, such as upfront milestones and
royalties for the license. We believe NPS has distinct features that would allow for us to find a suitable home for the asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Turning to SELLAS' financial position. The last
several months have provided to be truly transformative for the Company from a financial position standpoint. We ended the first quarter
with approximately $28 million in cash on hand, and provided guidance that we have runway for at least the next 12 months. Additionally,
since the end of the first quarter of '21 through June 1, we had sold shares of our common stock for net proceeds of approximately $3.8
million via the ATM facility, which has further strengthened our balance sheet. Our financing last December was at over 200% premium to
our previous financing last August and without warrants. Our capital structure has improved significantly with the exercise of the majority
of our previously outstanding warrants. And currently, warrants outstanding represent less than 4% of our total shares outstanding of
approximately 50.5 million shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously reported, our licensing agreement
with 3D Medicines for the Greater China territory has brought in $8.5 million of non-dilutive capital to date. And as I mentioned earlier,
we are pleased to report that just last week we triggered an additional $1 million milestone and expect to receive the proceeds before
the end of the second quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the increased strength of our
balance sheet and our cash position is the first step towards achieving our many important key milestones in 2021 and into 2022. We remain
focused on judicious capital allocation to our clinical programs and infrastructure to reach important inflection points and be appropriately
positioned for success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we open the call for questions to our research
analysts, I'd like to reiterate our belief that GPS has the potential to change the face of immunotherapy as we know it today. It has
the potential not only to help cancer patients in remission to live significantly longer, but also to provide patients with the opportunity
for a more tolerable, continuous treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We look forward to continuing to update you on
the progress of both our programs and to remind you of our shareholder meeting on June 8. If you have not done so yet, please submit your
votes. We appreciate your continued support as we work tirelessly to achieve the true value of SELLAS through our accomplishments over
the previous years and those to come.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you again for your time. Operator, please
open the call for questions now.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our first question comes from the line of Jason
McCarthy with Maxim Group. Please proceed with your question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jason McCarthy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Angelos. Thank you for taking the
questions. Maybe we could start with the NPS program and maybe you can help us understand a little bit more about the status of potential
partnering or collaborations and that kind of outreach, particularly coming out of not only the Phase 2b investigator study with Herceptin
and your triple negative data, but coming out of San Antonio Breast Cancer last December where we saw a significant amount of activity
from you and another group on the vaccine side. Does that really stoke interest around the space with Herceptin or even biosimilar Herceptin
makers?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Jason, for the question. Our business
development efforts really in seeking a license for the Phase 2 (inaudible) NPS asset are ongoing. As I mentioned earlier, it is very
important to us and for our shareholders, as well as our other stakeholders involved, MD Anderson Cancer Center and the Henry Jackson
Foundation, as well as really TNBC patients and their families and physicians that we find the right partner. We have made it a priority
to find a company that we believe has the financial resources, as well as the capability to really bring this to fruition from a clinical
development, regulatory and commercial perspective, and to truly execute on a Phase 3 program for NPS and successfully bring this product
to TNBC patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, we're particularly focusing, to your question
that you just raised, we're particularly focusing on companies with a presence in Asia as the data from the NPS studies have shown that
patients with the HLA types prevalent in Asia do particularly well. Also, as you correctly mentioned, given the data from the Phase 2b
study of NPS plus trastuzumab, or Herceptin, in TNBC patients, we believe that NPS could be of interest to companies either marketing
or developing a generic version of trastuzumab, and we have focused our outreach efforts on those companies. As I mentioned before, I
do believe that we'll find a suitable home for the asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jason McCarthy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Then, how about even with&mdash;sticking with
NPS for a second. Even beyond Herceptin and towards checkpoint inhibitors, just in the last year or two we've seen checkpoints now moving
into triple negative breast cancer and having success. Is there an opportunity there, and is that something you'd consider on the NPS
side of the SELLAS pipeline?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think that's an excellent question. As
you know, on the checkpoint blockade, we have done significant work with our lead asset, with GPS. Now with NPS, there's absolutely potential
to combine NPS with a checkpoint blockade. As you also know, we know the PD-1 companies very well. Suffice it to say, as I've alluded
to before, we will do what's really and truly in the best interest of our shareholders. It's Herceptin and there are potentially other
avenues as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jason McCarthy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Last question just on the checkpoint combination
side. Maybe you could talk just a little bit about the plans beyond AML. We know that that trial, the REGAL study's running and enrolling,
going quite nicely. Maybe talk a little bit about plans beyond that. Maybe you can just opine a little bit about what's changed in the
vaccine space where we've seen this resurgence in this because the checkpoints, which weren't there 10 years ago, not even five or six
years ago, are now there, they're in every line of therapy, which really opens up the conversation for cancer vaccines once again and
whether this valuation or value that's not been unlocked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I think, firstly, together with the Science
Committee of our Board, chaired by Dr. David Scheinberg, and our Scientific Advisory Board, we continue to explore other cancers, whether
it's a high WT1 expression and where it may make sense to pursue further clinical development of GPS, either alone or in combination.
We're very cautious of that. We're looking at different tumor types and what has potential market potential for GPS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, what's interesting with GPS, as you know,
there's a lack of target toxicity and GPS is generally well tolerated. Combined with overall ease of administration, we really believe
that GPS is well positioned for the current and future immuno-oncology landscape. We also believe that it can be combined with a wide
variety of other anticancer therapies. Perhaps not even just with PD-1, like we're seeing now with the ovarian cancer study, but also
with other I-O drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depending on the setting, we believe that GPS
could be given concurrently or sequentially. In more detail, based on the mechanism of action, as you correctly stated, GPS could be potentially
combined with other immuno activators, such as, again, CPBs, adjuvants, drugs that modulate HLAs, dendritic cells, macrophages, T-cells,
MAC inhibitors, Interleukins, superagonists. In principle, any active drug that is not immunosuppressive. And the application of GPS as
a monotherapy is optimal in the setting of minimal disease burden. Consequently, because this prior debulking of the disease is so important,
we believe that GPS, again, could be combined in sequence with any cytoreductive agent, as well as also radiotherapy as long as the chemotherapy
or combined modality therapy is not lympho depleting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What is interesting again with GPS, as I alluded
to earlier, the pharmacobiologic and the dynamic synergy among GPS and checkpoint blockade is true. There are about hundreds, thousands
of studies ongoing in combination of all sorts of drugs with PD-1 to almost like a trimera (phon) but it's very rare that there is a true
synergy that we have also seen in our previous studies. I think that's why we're very excited also with the issuance of the patent that
we recently received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think there's a great potential for GPS to unlock
even more value versus what it is today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jason McCarthy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sorry, I said last question, but you walked me
into another one that I want to ask, and I&rsquo;m not really sure if you're going to have the answer right now. Beyond PD-1 and CTLA-4,
you just mentioned, we're seeing a lot of activity now coming out of Bristol with LAG3 and it's going to be a big deal, we think, at ASCO.
Is that an area that you would consider going down as that space seems like it's heating up as the next checkpoint?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, also an excellent question. I think our clinical
team, Jason, is assessing various targets and combinatorial approaches. But just like in the fact with NPS that we're looking to find
a home for NPS, our Company's laser focused to create the most value for our shareholders, and I believe that it's not running hundreds
of studies and not being really laser focused on what we currently have on hand. Right now we have our Phase 3 AML study, with our PD-1
combinatorial studies, and we are looking for other avenues that really absolutely make sense, but we also don't want to go into chasing
a wild goose, if you will, to just go all over the place. We've never done it, and certainly under my watch and under the Board's watch,
we're not going to do that. We're going to be very laser focused to create the value that we really think and hope our shareholders would
appreciate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jason McCarthy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Angelos, thank you for taking all of those questions.
I'll turn it to the next analyst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Our next question comes from the line
of Jim Malloy with Alliance Global Partners. Please proceed with your question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Malloy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey guys. Thanks for taking my question. I just
had a follow-up question, so more on Jason's NPS question. How would you characterize the market for potential partners? Is it a buyers
market, a sellers market? Can you speak a little bit to perhaps trying to set expectations? I know it's hard to say a deal's done until
it's done. Certainly everyone understands that. But is there a way to set expectations on when you think a deal could potentially be reasonably
expected to conclude?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Jim, thank you for the question. I think
you've known me long enough to know that I would not speculate. And one thing, as I alluded to before, we're looking for the right partner.
There has been interest and we are looking for the right partner to again maximize shareholder value. But one thing that I can&mdash;I
think at this point where I'm standing today tell you is that SELLAS does not intend to develop NPS on its own, and I think that's something
that I've made very clear in previous discussions. We want to remain laser focused. If we had hundreds and hundreds of millions of dollars,
I would probably consider a different path, but we're very mindful here. To your point, I think we're looking for the right partner and
to create the value for the shareholders that they're all seeking, and rightfully so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Malloy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certainly understood. All right. Then on the nivo
combination with an IST, how much&mdash;I reviewed the data out on December 21 and it looked good, it's early and there's a few patients.
Obviously, that's the nature of early trials. How much control do you have over that trial and getting a handle on when the next data
points we should be looking for coming out?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, that's an excellent question, Jim. Unlike
the ovarian cancer study, where SELLAS is the sponsor, in collaboration with our partner, Merck, and as I mentioned before, we will be
disclosing the data this month once we assess it and review it carefully with Merck, the IST study is really, if you will, &quot;under
the auspices of Memorial Sloan Kettering&quot; and Bristol Meyers and SELLAS are collaborators. As far as I can tell you, I'm positive
that we will have data this month, but again since we're not the sponsor we rely if you will, on Memorial Sloan Kettering. But the recent
discussions that we have had does not lead me to believe that we're not going to meet the timeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both for ovarian cancer and mesothelioma, we expect
the data this month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Malloy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Perfect. Maybe last question. Coming to (inaudible)
the U.S., of course, of the impact of COVID. Could you speak a little bit to how it's impacted your trials? You guys have adapted. What
changes are you seeing on the clinical trial front as things, at least, again, in the U.S. and some of Europe seem to be ameliorating?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I appreciate that question, Jim. You and
I have discussed this a while back, but despite COVID, as I mentioned earlier, we remain clear in our mission and vision to develop innovative
treatments for patients battling cancer. During the past 15 months, I think we managed those elements of our business that we were able
to control during the pandemic. That is, progressing our assets, generating clinical and immunobiological data, executing on our corporate
plan and progressing with business development opportunities. As you saw, 2020 was a very, very busy year for SELLAS and a successful
year, if I may add.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent at which COVID has affected our
clinical program, it's difficult to gauge. We certainly noticed delays in initiating clinical sites, both in the U.S. and Europe, because
of lockdowns and work from home restrictions. However, we continue to screen and enroll patients in all of our ongoing studies, as well
as activating additional sites in the United States and Europe for the REGAL study and part of the plan that we implemented when we saw
the issues around COVID was to increase the number of sites so we acted and reacted very quickly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full extent to which the COVID pandemic directly
or indirectly impacts the Company's business, results of operations and financial conditions going forward will depend on future developments
that are highly uncertain and subject to change certainly. But we're very careful and mindful. We're looking at the new geographic hot
spots where the coronavirus is or may be spreading more rapidly. But rest assured, as we have done in the past, we'll do whatever we can
throughout this pandemic to execute on our corporate goals. We owe it to our shareholders, as well as to patients in need. I just want
to stress once more, just please, everyone, get vaccinated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group, Inc. &ndash; Shareholder
Update Call, June 3, 2021</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Malloy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Well, thank you for taking the questions, and
continued success on the clinical development. It's been an active year. It looks like a busy year coming up as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Jim. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Ladies and gentlemen, this concludes
our question-and-answer session. I'll turn the floor back to Dr. Stergiou for any final comments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Angelos Stergiou</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, thank you. I would just like to thank everyone
for joining us today. I appreciate the time you all took to listen to our shareholder update. Again, we wouldn't be here without you and
we very much look forward to providing continuous updates on our clinical development and operational programs and commercial strategies.
Thank you again, and stay safe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. This concludes today's conference.
You may disconnect your lines at this time. Thank you for your participation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide
an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference
call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 <U>www.viavid.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Additional Information and Where to Find it</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">SELLAS
Life Sciences Group, Inc. (&ldquo;SELLAS&rdquo;)</FONT> filed with the SEC a proxy statement for its stockholders (the &ldquo;Proxy Statement&rdquo;).
SELLAS sent the Proxy Statement to its stockholders and may file other documents regarding the proposals therein with the SEC. This communication
is not a substitute for the Proxy Statement or any other document that SELLAS may send to its stockholders in connection with the proposals
therein.&nbsp;INVESTORS AND SECURITY HOLDERS OF SELLAS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS (INCLUDING
ANY AMENDMENTS OR SUPPLEMENTS THERETO) THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SELLAS, THE PROPOSALS AND RELATED MATTERS.&nbsp;Investors and security holders of SELLAS
are able to obtain free copies of the Proxy Statement and other documents (including any amendments or supplements thereto) containing
important information about SELLAS, through the website maintained by the SEC at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Participants in the Solicitation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SELLAS and certain of its directors and executive officers may be deemed
to be participants in the solicitation of proxies from the stockholders of SELLAS in respect of the proposals contemplated by the proxy
statement. Information regarding SELLAS&rsquo; directors and executive officers is contained in SELLAS&rsquo; Annual Report on&nbsp;Form&nbsp;10-K&nbsp;for
the year ended December 31, 2020 and in the&nbsp;proxy statement&nbsp;for SELLAS&rsquo; 2021 annual meeting of stockholders on&nbsp;Schedule
14A, dated April 23, 2021, both of which are filed with the SEC. Additional information regarding the persons who are, under the rules
of the SEC, participants in the solicitation of the stockholders of SELLAS in connection with the proposals, including a description of
their direct or indirect interests, by security holdings or otherwise, are set forth in the proxy statement that is filed with the SEC,
free copies of which may be obtained as described in the preceding paragraph. To the extent holdings of SELLAS&rsquo; securities by SELLAS&rsquo;
directors and executive officers change since the amounts set forth in the proxy statement for SELLAS&rsquo; 2021 annual meeting of stockholders,
such changes have been or will be reflected on Statements of Change in Ownership on&nbsp;Form 4&nbsp;filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Forward-Looking Statements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">These materials contain forward-looking
statements. All statements other than statements of historical facts are &ldquo;forward-looking statements,&rdquo; including those relating
to future events. In some cases, forward-looking statements can be identified by terminology such as &ldquo;plan,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;anticipate,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;project,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;continue&rdquo; and other words
or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS for various
cancer indications, the potential for regulatory approval and commercialization of GPS, the potential for additional milestone payments
under SELLAS&rsquo; license agreement, and the clinical development of NPS for breast cancer. These forward-looking statements are based
on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact
on the Company&rsquo;s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success
thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set
forth under the caption &ldquo;Risk Factors&rdquo; in SELLAS&rsquo; Annual Report on Form 10-K filed on March 23, 2021 and in its other
SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&rsquo; forward-looking statements
and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein
are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect
actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which
the forward-looking statements were made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #474747">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #474747"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #474747">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2118805d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2118805d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (" LX# 2(  A$! Q$!_\0
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MO^#.V_X;DM?^A=N/_ P?_$4?\-R6O_0NW'_@8/\ XBN)_P"&:O\ J-?^2?\
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M\E/_ +.C_AG+_J,_^2G_ -G3^K5.P?7J'\WX,[K_ (;DM?\ H7;C_P #!_\
M$4?\-R6O_0NW'_@8/_B*X7_AG+_J,_\ DI_]G0?V<O\ J,?^2G_V=+V%3L'U
MZA_-^#.Z_P"&Y+7_ *%VX_\  P?_ !%'_#<EK_T+MQ_X&#_XBN#_ .&=?^HQ
M_P"2G_V='_#.W_48_P#)3_[.G]6J=@^O4/YOP9WG_#<EK_T+MQ_X&#_XBC_A
MN2U_Z%VX_P# P?\ Q%<'_P ,[?\ 48_\E/\ [.FG]G?'_,7_ /)3_P"SH^K5
M.POK]#^;\&=]_P -R6O_ $+MQ_X&#_XBC_AN2U_Z%VX_\#!_\17 _P##//\
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MEK_T+MQ_X&#_ .(H_P"&Y+7_ *%VX_\  P?_ !%>(GPA_P!/'_D/_P"O3?\
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M]R1M'6BBEL(84Q7V_P#";_DE?AK_ +!5K_Z)2OB.OMSX4?\ )+?#7_8*M?\
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M+Z?/EVL*\L[8!.!["OFO_A^7^R9_T6_PG_WQ<_\ QJNA_P""QRX_X):_'?\
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M'3O@WX0?M ZSX*\,_"^X\>>&-$O9=,U+6)M:6S%\4)CE^SP^1('C#!L,[#S
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MC)BF0T0,F:8RYJ=DS3&7-4F25WCIA&*L,N*8\>:HS<2%ES7V#\,O^2;>'O\
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MI]O&-Q'3'0E:]-\"_ W3_ 7QE\=^-;>[O)K_ ,??V?\ ;()-ODV_V.!H4\O
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MRO4V[%#J <4447[C'JV:6HZ57Q0UV ?11G-%2 !L4\-FF44#N244U7IU!6X
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MIDM$3Q\5"\=6>E-9,TTR&BHRYIC+BK+Q5&RXJC-H@9*^F_ /_(B:+_UX0?\
MHM:^:&2OICP%_P B-HO_ %X0?^BUKS<S^&)]!PZK5)^AXK^W1_S*_P#V]_\
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M7-3M'BF,N:HD@(Q7T9X(_P"1+TC_ *\H?_1:U\[LN*^B/!''@S2/^O*'_P!
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M=:_#RTF\:V-POABVM5M8] ,DNER-:")8XPAC9F4CRTY4_*.E6/A#_P $]O\
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M[Q3*Y.75IYV.[*#<%K[3^!7_  01\;:S_P $KO%W[,7Q?\8^%Y[.R\3-XB\
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M!O@?\#M4^.&A0>)?'%F^L:W\5M0\ QB/POH^/+MH+?2;194FE7RW0,5.=B9
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M5T-Z9;IB4\\M%# 9%C25%9XE#?*S9\2_:-_X(<?ME?M,_L ?#[X%Z_\ $GX
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MNZ-8>&;2T-_/J]S>QQ6,-L%W&9IV81K&%YW$XQSFHNGH79F\KXIZMBL#X?\
MQ&T#XK>#['Q#X7US1_$N@:FADL]3TJ]CO+.[4,5)CEC+(X#*PR">01VK;5L4
M%>I.&S2U$K9IZO1Z#'JV*<#FF5ROC3X[>"?AKXST#P[XB\8^%= \0^*Y3#HF
MEZEJUO:WFLR JI2VAD</,P+J,("<L/45)6KV.NH!Q2*V:6F%QZMFEKF_B?\
M%GPM\$O!UQXB\9^)?#_A'P_:,B3ZGK6HPV%G"SL$0--*RHI9B ,GDD 5KZ#X
M@LO%&B6>I:;>6NHZ;J,"75I=VLJS07,3J&21'4E61E((8$@@@BHMV+UM<NT
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M*6E_]>D7_H KPRO<_"/_ "*FF?\ 7I%_Z *X<?\ "CV,E^.7H>(?MT?\RO\
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MH)1\_P ]#\IOVM#C_@[6_9@_[)E>_P#I-XGIW_!P&V?^"EO_  3E_P"RFO\
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M?[)7Q5@_X-==?^'[_#+X@KX\F\7+<Q^&SX=O!J[Q?VI;OY@M?+\XKL4MG;C
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MK&B:A#&L22""VEBED7;&AY<)^]DR044'Z,_X(-?L=W7[/_A'XC>-+SX(Z/\
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MP=I<4EK;>,KMX4$_GSQS1F-!*AVC8VU6DVD%]X\._P""*7BG1_ __!8CX_\
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ME7U:MU@_N9@ALTM;O_"I/%?_ $+/B'_P73?_ !-.7X3>*_\ H6?$/_@NF_\
MB:/;4_YE]X_JM=?8?W,P5?%/!S6Y_P *E\5?]"SX@_\ !=-_\32CX3>*Q_S+
M/B#_ ,%TW_Q-'MJ?\R^\?U6O_(_N9A4 XK?'PG\5'_F6?$'_ (+IO_B:7_A4
MWBK_ *%KQ!_X+IO_ (FCVU/^9?>'U6O_ "/[F82MFEK<_P"%3>*O^A:\0?\
M@NF_^)IR_"GQ5_T+7B#_ ,%TW_Q-3[2G_,BOJU;^1_<S!H!Q6_\ \*H\4_\
M0M:__P""Z;_XFC_A5'BG_H6M?_\ !=-_\32]M#NA_5:W\C^YF$KYIU;?_"J/
M%/\ T+6O_P#@NF_^)IR_"KQ2/^9:U_\ \%\W_P 31[6GTDOO']6K_P C^YF$
M&Q4B25M_\*I\4?\ 0MZ__P""^;_XFC_A57BC_H6]?_\ !?-_\32]K#NBEAJW
M\C^YF1G-*KXK93X6^*1_S+>O_P#@OF_^)IX^%OB<_P#,N:]_X+Y?_B:7M:?=
M%?5JW\C^YF,#FBMH?"WQ./\ F7->_P#!?+_\33Q\+O$Q_P"9<U[_ ,%\O_Q-
M3[2"^TBOJ];^1_<S$23!J56S6M_PJWQ-_P!"YKO_ (+Y?_B:5?A?XG'_ #+N
MN_\ @!+_ /$T>UIOJBEAZW\C^YF6KTZM9?AEXF_Z%W7?_ "7_P")IX^&7B4?
M\R]KG_@!+_\ $TO:P[HOZO6_E?W,R%>G9K7'PR\2'_F7M<_\ )?_ (FG#X9^
M)1_S+VN?^ $O_P 34NI#NBE0K?RO[F9"OBI%?-:H^&?B0C_D7]<_\ )?_B:4
M?#3Q(/\ F7];_P# &7_XFI]K#NBU0K?RO[F9BOBGJV*U%^&_B/\ Z%_6_P#P
M!E_^)IX^&_B,?\P#6O\ P!E_^)H]I#NC54*O\K^XRU;-/5ZTQ\./$1_Y@&M?
M^ ,O_P 33U^'7B+_ * .M?\ @#+_ /$U'M(=T5["K_*_N,Q7Q4B29K17X=>(
M1_S =9_\ I?_ (FGCX=^(?\ H!:S_P" 4G_Q-+VD.Z*]A5_E?W&=FG+)BM)/
MA]X@'_,"UG_P"D_^)J0?#W7_ /H!ZQ_X!2?X5//#N6J-7^5_<9ROFGJ]7Q\/
MO$ _Y@>L?^ 4G^%2+X!U_P#Z >L?^ <G^%3[2'<T5&K_ "O[C.5L4]6S6@O@
M'7A_S!-7_P# .3_"GCP%KO\ T!=7_P# .3_"ESQ[E>QJ_P K^XSU?-/5\5H+
MX#UT_P#,%U;_ , Y/\*<O@371_S!=6_\ Y/\*GGCW*5*I_*_N*22U*&S5L>!
M=<'_ #!M5_\  23_  IZ>"-<_P"@-JO_ ("2?X5+E'N6J53^5_<4@<4]6S5]
M?!.M'_F#ZI_X"2?X4[_A"-:_Z!&J?^ DG^%3SQ[EJE4_E?W%%7IZMBKJ^"M:
M_P"@1JG_ ("2?X4Y?!>M#_F$:G_X"O\ X4<\>Y?LJG\K^XJ))FI%;%6AX+UG
M_H$ZG_X"O_A3T\'ZR/\ F$ZG_P" K_X4G*/<KV<_Y7]Q4!S3@V*NCP=J_P#T
M"M2_\!7_ ,*</"&KG_F%:E_X#/\ X5'/'N5[.IV925LT]7S5O_A#]7'_ #"]
M1_\  9_\*>OA'5S_ ,PO4?\ P&?_  I<\>Y?LY]F4\T]),5;7PEJP_YA>H_^
M S_X4[_A$=5_Z!FH?^ S_P"%+FCT8_9U.S*P;-*#BK2^%-6'_,,U#_P&?_"I
M%\+:J?\ F&:A_P" S_X4N:/<KV<^S*@;-*#@U;_X135/^@;?_P#@._\ A3E\
M+ZI_T#;_ /\  =_\*7-'N5[.?9E56S3U>K/_  BVI_\ 0.O_ /P'?_"G+X8U
M3_H'7_\ X#O_ (4KQZ,I0GV975L4X'-6!X8U,?\ ,.OO_ =_\*>/#.I?] ^^
M_P# =O\ "ESQ[E\D^S*M*KXJV/#>I'_F'WW_ 'X;_"E_X1K4?^@?>_\ ?AO\
M*7,NX_9S[%;.:*M#PWJ0_P"8?>_]^&_PIP\.:B?^7"]_[\-_A1S+N/DGV*8.
M*>&S5K_A&]1_Y\+W_OPW^%'_  C>H_\ /A>_]^&_PI7B^H^278K45;7P]J/_
M #X7O_?AO\*7_A'-0_Y\+S_OPW^%3S)=1\D^Q3!P:>K9JS_PCFH?\^%Y_P!^
M&_PH_P"$<U#_ )\+S_OPW^%5S1?4?)+L5Z*M+X?U#_GQO/\ OPW^%._X1[4/
M^?&\_P"_+?X5-UW#DEV*=*&Q5O\ X1[4/^?&\_[\M_A1_P (]J'_ #XWG_?E
MO\*7,@Y)]BL&S2U8_P"$>U#_ )\;S_ORW^%.70+_ /Y\;S_ORW^%',BN678J
MT XJW_PC]_\ \^5W_P!^6_PH_P"$?O\ _GRN_P#ORW^%',@]G+HBN&S2U/\
M\(_?_P#/E=_]^6_PIRZ%?_\ /E=_]^6_PHYD"C+L5J*M_P!@WW_/E=_]^6_P
MH_L&^_Y\KO\ [\M_A1S(KDEV*E>FZ!_R K+_ *X)_P"@BO/?[!OO^?*[_P"_
M+?X5Z'HD;1:-:*P*LL* @C!!VBN7%--*QZ&7Q:D[EJBBBN,]4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
